Journal article
Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age
Abstract
Importance: Sodium polystyrene sulfonate is commonly prescribed for the treatment of hyperkalemia. Case reports of intestinal injury after administration of sodium polystyrene sulfonate with sorbitol resulted in a US Food and Drug Administration warning and discontinuation of combined 70% sorbitol-sodium polystyrene sulfonate formulations. There are ongoing concerns about the gastrointestinal (GI) safety of sodium polystyrene sulfonate use.
Authors
Noel JA; Bota SE; Petrcich W; Garg AX; Carrero JJ; Harel Z; Tangri N; Clark EG; Komenda P; Sood MM
Journal
JAMA Internal Medicine, Vol. 179, No. 8, pp. 1025–1033
Publisher
American Medical Association (AMA)
Publication Date
August 1, 2019
DOI
10.1001/jamainternmed.2019.0631
ISSN
2168-6106